Cargando…

Atazanavir–bilirubin interaction: a pharmacokinetic–pharmacodynamic model

PURPOSE: The aim of this work was to analyze the atazanavir–bilirubin relationship, using a new mathematical approach to pharmacokinetic–pharmacodynamic models, for competitive drug interactions based on Michaelis–Menten equations. PATIENTS AND METHODS: Because atazanavir induces an increase of plas...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lozano, Roberto, Domeque, Nieves, Apesteguia, Alberto-Fermin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2013
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3792011/ https://www.ncbi.nlm.nih.gov/pubmed/24106429 http://dx.doi.org/10.2147/CPAA.S48377

Ejemplares similares

Atazanavir–bilirubin interaction: a pharmacokinetic–pharmacodynamic model [Corrigendum]
Publicado: (2013)

Pharmacokinetic-pharmacodynamic modelling of atazanavir in hair among adolescents on antiretroviral treatment in Zimbabwe
por: Ngara, Bernard, et al.
Publicado: (2021)

External Validation of the Bilirubin–Atazanavir Nomogram for Assessment of Atazanavir Plasma Exposure in HIV-1-Infected Patients
por: Rekić, Dinko, et al.
Publicado: (2012)

Race/ethnicity difference in the pharmacogenetics of bilirubin-related atazanavir discontinuation
por: Leger, Paul, et al.
Publicado: (2018)

Predictors of the change in bilirubin levels over twelve weeks of treatment with atazanavir
por: Cotter, Aoife G, et al.
Publicado: (2013)

Population pharmacokinetics of ritonavir-boosted atazanavir in HIV-infected patients and healthy volunteers
por: Dickinson, Laura, et al.
Publicado: (2009)

Antenatal Atazanavir: A Retrospective Analysis of Pregnancies Exposed to Atazanavir
por: Samuel, Miriam, et al.
Publicado: (2014)

Population Pharmacokinetics Modeling of Unbound Efavirenz, Atazanavir, and Ritonavir in HIV‐Infected Subjects With Aging Biomarkers
por: Dumond, JB, et al.
Publicado: (2016)

Interaction of p-synephrine on the pharmacodynamics and pharmacokinetics of gliclazide in animal models
por: Vatsavai, Leela Krishna, et al.
Publicado: (2018)

Atazanavir nephrotoxicity
por: Hara, Masaki, et al.
Publicado: (2015)

The Overview on the Pharmacokinetic and Pharmacodynamic Interactions of Triazoles
por: Czyrski, Andrzej, et al.
Publicado: (2021)

Pharmacokinetics, Pharmacodynamics and Population Pharmacokinetic/Pharmacodynamic Modelling of Bilastine, a Second-Generation Antihistamine, in Healthy Japanese Subjects
por: Togawa, Michinori, et al.
Publicado: (2016)

A review of pharmacokinetic and pharmacodynamic interactions with antipsychotics
por: Wijesinghe, Ruki
Publicado: (2016)

Evaluation of pharmacokinetics of warfarin from validated pharmacokinetic-pharmacodynamic model
por: Sridharan, Kannan, et al.
Publicado: (2021)

Oxycodone-Related Deaths: The Significance of Pharmacokinetic and Pharmacodynamic Drug Interactions
por: Jakobsson, Gerd, et al.
Publicado: (2022)

An Approach for Identifiability of Population Pharmacokinetic–Pharmacodynamic Models
por: Shivva, V, et al.
Publicado: (2013)

Pharmacodynamic Parameters of Pharmacokinetic/Pharmacodynamic (PK/PD) Integration Models
por: Zhang, Longfei, et al.
Publicado: (2022)

Influence of curcumin on the pharmacodynamics and pharmacokinetics of gliclazide in animal models
por: Vatsavai, Leela Krishna, et al.
Publicado: (2016)

Predicting Drug–Drug Interactions between Rifampicin and Ritonavir-Boosted Atazanavir Using PBPK Modelling
por: Montanha, Maiara Camotti, et al.
Publicado: (2021)

Pharmacodynamic and Pharmacokinetic Interactions of Propranolol with Garlic (Allium sativum) in Rats
por: Asdaq, Syed Mohammed Basheeruddin, et al.
Publicado: (2011)

Pharmacokinetic and pharmacodynamic interaction of Rosuvastatin calcium with guggulipid extract in rats
por: Asad, Mohammed, et al.
Publicado: (2021)

Pharmacokinetic and pharmacodynamic interaction between ezetimibe and rosuvastatin in healthy male subjects
por: Kim, Chang Hee, et al.
Publicado: (2017)

Pharmacokinetic/Pharmacodynamic Interaction Between Evogliptin and Pioglitazone in Healthy Male Subjects
por: Hwang, Inyoung, et al.
Publicado: (2020)

Pharmacokinetic/Pharmacodynamic Interactions Between Evogliptin and Glimepiride in Healthy Male Subjects
por: Yoo, Hyounggyoon, et al.
Publicado: (2020)

Fractional dynamics pharmacokinetics–pharmacodynamic models
por: Verotta, Davide
Publicado: (2010)

A pharmacokinetic and pharmacodynamic drug interaction between rosuvastatin and valsartan in healthy subjects
por: Jung, Jin Ah, et al.
Publicado: (2015)

Absence of Pharmacokinetic and Pharmacodynamic Interactions between Almorexant and Warfarin in Healthy Subjects
por: Dingemanse, Jasper, et al.
Publicado: (2013)

Review of Tolvaptan’s Pharmacokinetic and Pharmacodynamic Properties and Drug Interactions
por: Bhatt, Purav R., et al.
Publicado: (2014)

Comorbid epilepsy and depression—pharmacokinetic and pharmacodynamic drug interactions
por: Miziak, Barbara, et al.
Publicado: (2022)

Coadministered cannabidiol and clobazam: Preclinical evidence for both pharmacodynamic and pharmacokinetic interactions
por: Anderson, Lyndsey L., et al.
Publicado: (2019)

Pharmacokinetics and Pharmacodynamics of Posaconazole
por: Chen, Lu, et al.
Publicado: (2020)

Pharmacokinetics and Pharmacodynamics of Ibrexafungerp
por: McCarthy, Matthew William
Publicado: (2021)

Pharmacokinetics and Pharmacodynamics of Tedizolid
por: Iqbal, Khalid, et al.
Publicado: (2022)

Evaluation of the pharmacokinetic and pharmacodynamic drug interactions between cilnidipine and valsartan, in healthy volunteers
por: Lee, Jieon, et al.
Publicado: (2014)

Evaluating Pharmacokinetic and Pharmacodynamic Interactions with Computational Models in Supporting Cumulative Risk Assessment
por: Tan, Yu-Mei, et al.
Publicado: (2011)

A systematic review of the pharmacokinetic and pharmacodynamic interactions of herbal medicine with warfarin
por: Choi, Songie, et al.
Publicado: (2017)

Metabolic and Kidney Disorders Correlate with High Atazanavir Concentrations in HIV-Infected Patients: Is It Time to Revise Atazanavir Dosages?
por: Gervasoni, Cristina, et al.
Publicado: (2015)

Pharmacokinetics and pharmacodynamics of cyclopropylfentanyl in male rats
por: Bergh, Marianne Skov-Skov, et al.
Publicado: (2021)

Pharmacokinetics/Pharmacodynamics models of veterinary antimicrobial agents
por: Luo, Wanhe, et al.
Publicado: (2019)

Pharmacokinetic–Pharmacodynamic Modeling of Midazolam in Pediatric Surgery
por: Flores-Pérez, Carmen, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_6von4qoi4mdugjje72r20fodpd